A phase 2 study evaluated the use of ruxolitinib plus standard GVHD prophylaxis in patients with myelofibrosis undergoing ...
Race may play a role in the waitlist experience, allograft quality and transplant outcomes of patients with autosomal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback